MRKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (7 5月 2024 @ 05:03):

Stats
本日の出来高	6.55M
平均出来高	8.23M
時価総額	323.09B
EPS	$0.0300 ( 2024-04-25 )
次の収益日	( $1.870 ) 2024-05-28
Last Dividend	$0.770 ( 2023-12-14 )
Next Dividend	$0 ( N/A )
P/E	140.19
ATR14	$0.0390 (0.03%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-04	Smart Dalton	Buy	612	Common Stock
2024-05-03	Smart Dalton	Buy	1 530	Common Stock
2024-05-04	Smart Dalton	Sell	302	Common Stock
2024-05-03	Smart Dalton	Sell	590	Common Stock
2024-05-03	Smart Dalton	Buy	516	Common Stock

INSIDER POWER
25.86
Last 99 transactions
Buy: 1 325 861 \| Sell: 852 034

ボリューム相関

長: 0.06 (neutral)

短: 0.92 (very strong)

Signal:(59.144) Expect same movement, but be aware

Merck & Co Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Merck & Co Inc 相関 - 通貨/商品

-0.36
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.54
( weak negative )

0.56
( weak )

-0.43
( neutral )

Merck & Co Inc 財務諸表

Annual	2023
収益:	$59.87B
総利益:	$43.89B (73.31 %)
EPS:	$0.140

FY	2023
収益:	$59.87B
総利益:	$43.89B (73.31 %)
EPS:	$0.140

FY	2022
収益:	$59.28B
総利益:	$41.87B (70.63 %)
EPS:	$5.73

FY	2021
収益:	$48.70B
総利益:	$35.08B (72.02 %)
EPS:	$5.16

Financial Reports:

No articles found.

Merck & Co Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.690 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.730 (N/A)	$0.770 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Merck & Co Inc Dividend Information - Dividend King

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.58 - Stable (31.51%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00663	1970-06-02
Last Dividend	$0.770	2023-12-14
Next Dividend	$0	N/A
Payout Date	2024-01-08
Next Payout Date	N/A
# dividends	214	--
Total Paid Out	$52.58	--
Avg. Dividend % Per Year	2.07%	--
Score	6.02	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.58
Div. Directional Score	8.99	--

Next Divdend (Est)
(2024-07-08)

$0.776 Estimate 39.86 %

Dividend Stability

0.80 Good

Dividend Score

6.02

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1970	$0.0206	1.40%
1971	$0.0292	2.31%
1972	$0.0224	1.35%
1973	$0.0327	1.36%
1974	$0.0278	1.31%
1975	$0.0371	2.09%
1976	$0.0378	2.04%
1977	$0.0411	2.31%
1978	$0.0465	3.27%
1979	$0.0530	2.94%
1980	$0.0628	3.34%
1981	$0.0702	3.08%
1982	$0.0744	3.28%
1983	$0.0757	3.39%
1984	$0.0809	3.37%
1985	$0.0875	3.54%
1986	$0.106	2.90%
1987	$0.143	2.14%
1988	$0.208	2.38%
1989	$0.274	3.01%
1990	$0.321	2.57%
1991	$0.378	2.66%
1992	$0.458	1.73%
1993	$0.506	2.42%
1994	$0.554	3.29%
1995	$0.610	3.34%
1996	$0.706	2.30%
1997	$0.830	2.18%
1998	$0.946	1.84%
1999	$1.070	1.50%
2000	$1.202	1.86%
2001	$1.316	1.48%
2002	$1.356	2.38%
2003	$4.14	7.45%
2004	$1.432	3.19%
2005	$1.452	4.87%
2006	$1.452	4.65%
2007	$1.452	3.46%
2008	$1.452	2.65%
2009	$1.452	4.91%
2010	$1.452	4.11%
2011	$1.490	4.33%
2012	$1.613	4.41%
2013	$1.650	4.18%
2014	$1.689	3.58%
2015	$1.726	3.16%
2016	$1.765	3.52%
2017	$1.802	3.14%
2018	$1.899	3.54%
2019	$2.16	2.99%
2020	$2.37	2.69%
2021	$2.61	3.38%
2022	$2.80	3.64%
2023	$2.96	2.66%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0375	1.500	9.25	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0218	1.200	9.27	10.00	[0 - 0.3]
returnOnEquityTTM	0.0584	1.500	-0.462	-0.693	[0.1 - 1]
payoutRatioTTM	2.42	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.253	0.800	8.74	6.99	[1 - 3]
quickRatioTTM	0.728	0.800	-0.421	-0.337	[0.8 - 2.5]
cashRatioTTM	0.226	1.500	9.86	10.00	[0.2 - 2]
debtRatioTTM	0.323	-1.500	4.61	-6.92	[0 - 0.6]
interestCoverageTTM	7.47	1.000	8.34	8.34	[3 - 30]
operatingCashFlowPerShareTTM	5.83	2.00	8.06	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.36	2.00	7.82	10.00	[0 - 20]
debtEquityRatioTTM	0.848	-1.500	6.61	-9.91	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.889	0.889	[0.2 - 0.8]
operatingProfitMarginTTM	0.110	1.000	9.80	9.80	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.431	1.000	8.72	8.72	[0.2 - 2]
assetTurnoverTTM	0.580	0.800	9.46	7.57	[0.5 - 2]
Total Score				11.41

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	140.13	1.000	10.00	0	[1 - 100]
returnOnEquityTTM	0.0584	2.50	-0.297	-0.693	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.36	2.00	8.55	10.00	[0 - 30]
dividendYielPercentageTTM	2.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.83	2.00	8.06	10.00	[0 - 30]
payoutRatioTTM	2.42	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	4.77	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.240	1.000	6.49	0	[0.1 - 0.5]
Total Score				6.58

Merck & Co Inc

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.